trending Market Intelligence /marketintelligence/en/news-insights/trending/fxzfikoklmkhmgfm_aw1mq2 content esgSubNav
In This List

Guggenheim Securities names senior biotech analyst

Blog

Balance Sheet Strategy in an Unusual Rate Environment

Podcast

Street Talk | Episode 98: Regulatory scrutiny having cooling effect on community bank M&A

Blog

Insight Weekly: M&A outlook; US community bank margins; green hydrogen players' EU expansion

Blog

Global M&A by the Numbers: Q2 2022


Guggenheim Securities names senior biotech analyst

Michael Schmidt will join Guggenheim Securities in June as a senior analyst and senior managing director as part of the company's expansion of its healthcare research team.

Schmidt will focus on the coverage of biotech companies and will work closely with its therapeutics team.

He has served as an equity research analyst at LEERINK Partners since 2009.

Guggenheim Securities is the investment banking and capital markets division of Guggenheim Partners.